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Abstract Despite extensive knowledge about quality of life of people suffering
from dermatological diseases, data on patients with morphea are scarce. The
aim of our study was to compare the quality of life of healthy controls and
morphea patients, as well as to determine the correlation of this variable with
the level of dispositional optimism. The study included 47 patients with
morphea and 47 healthy controls, matched for gender and age. Cantril’s Ladder
and Life Orientation Test-Revised were used to assess the levels of life satis-
faction and dispositional optimism, respectively. LoSSI was used for the objec-
tive assessment. The anticipated level of life quality and the level of disposi-
tional optimism were statistically significantly lower in morphea patients (p=
0.032 and p=0.014, respectively) when compared to controls. There were no
differences in the assessment of current (p=0.168) and past (p=0.318) levels of
life quality. Also, we proved that type of morphea did not differentiate the
current (p=0.175), past (p=0.620) and future (p=0.356) assessment of the
quality of life. In the group of morphea patients there was a statistically
significant correlation between the level of dispositional optimism and current
(p=0.002, r=0.43), as well as anticipated (p<0.001, r=0.57) levels of life
quality. Current level of life quality of healthy controls and morphea patients
is comparable, whereas the latter anticipate their future life situation to be
significantly worse than the former. Higher level of life satisfaction correlates
with higher level of optimism.
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Introduction
Sclerodermatous diseases are characterized by hardening of the skin resulting from
fibrosis of the skin and subcutaneous tissue, occurring in the course of not fully
understood pathogenetic processes (Peterson et al. 1995; Kreuter et al. 2009; Gupta
and Fiorentino 2007). The group of sclerodermatous diseases includes systemic scle-
rosis, morphea (localized scleroderma, scleroderma circumscripta), as well as numerous
sclerodermatous-like diseases such as premature aging syndromes, sclerodermatous
graft-versus-host disease, porphyria cutanea tarda and others (Peterson et al. 1995;
Kreuter et al. 2009; Gupta and Fiorentino 2007).
Unlike systemic sclerosis, morphea essentially affects the skin. In cases of reported
involvement of the internal organs, it is either subclinical or the symptoms are discrete
(Peterson et al. 1995; Kreuter et al. 2009; Gupta and Fiorentino 2007; Christen-Zaech
et al. 2008). No negative correlation between morphea and life expectancy of patients
has been reported (Peterson et al. 1997). The symptoms are limited mostly to single
patches of hardened skin, located most often on the torso, like in case of plaque
morphea (morphea en plaques—MEP), but they may also involve larger areas of the
skin, like in the case of generalized morphea (GM). A more unique type of the disease,
linear morphea (LM), is found usually on the extremities or the face and may lead to
considerable deformities such as hemiatrophy of the face, alopecia, dermatogenic
contractures and/or shortening of the extremities. Movement limitation and contractures
are also found in the course of deep morphea (DM) (Peterson et al. 1995; Kreuter et al.
2009; Gupta and Fiorentino 2007; Christen-Zaech et al. 2008; Dehen et al. 1994;
Bergler-Czop et al. 2005). However, after approximately 2–6 years, the hardening of
the skin shows a marked tendency to soften (Peterson et al. 1997; Marzano et al. 2003).
Nevertheless, the changes in the affected places such as atrophy, discolouration or
depigmentation are permanent in nature. Contractures, most often related to LM, do not
show any regressive tendencies (Peterson et al. 1995). Sometimes, after the time of
remission or stabilization, the disease becomes active (Christen-Zaech et al. 2008;
Peterson et al. 1997; Marzano et al. 2003).
Undoubtedly, morphea patients experience various problems and symptoms,
resulting in dissatisfaction with life and its quality.
The term ‘quality of life’ is used in numerous contexts and perceived as a feature of
character, attitude, emotional state or response to stimuli. It is associated with the
satisfaction of needs, positive attitude to life or with the level of life satisfaction
(Dziurowicz-Kozłowska 2002). Despite extensive data about the quality of life of
dermatological patients, relatively little is known about people suffering from morphea.
Thus, the aim of our study was to compare the quality of life of healthy controls and
morphea patients, as well as to determine the correlation of this variable with the level
of dispositional optimism.
According to Schier, dispositional optimism constitutes a part of personality that
manifests itself in a general expectation of positive events (Poprawa and Juszczyński
2001). Countless investigations proved that it promotes physical and psychological
wellbeing, success in life and stress immunity (Poprawa and Juszczyński 2001). In
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challenging situations pessimists experience distress, whereas optimists attempt to see
the positive aspects of the events (Schier and Carver 1992; Carver et al. 2010; Seligman




The research was conducted between September 2011 and October 2012. The Bioeth-
ics Committee of the Poznań University of Medical Sciences approved of the study
(approval No. 25/10). The study included 94 participants: 47 morphea patients of the
Dermatology Clinic, Poznań University of Medical Sciences, and 47 healthy
volunteers. Purposive sampling technique was used to assign patients to the
study and control groups. First, morphea patients free of any psychological
disorders and other chronic diseases were examined. The diagnosis was based
on the clinical criteria and confirmed with a histology test. The control group
was established by matching each subject with a healthy control of the same
gender and similar age (+/−2 years). The study group, mean age 42 years (min.
18, max. 72), comprised of 47 people: 30 females and 17 males. 26.6 % of the
subjects were diagnosed with MEP (16 F and 9 M), 11.7 % with GM (4 F and
7 M), 10.6 % with LM (9 F and 1 M), and 1.1 % with DM (1 F).
Assessment of the Level of Life Quality
Cantril’s Ladder is widely used to assess the levels of life quality, life satisfaction or the
so-called positive health (Mazur et al. 2009; Currie et al. 2004). This popular tool is a
component of a set of questionnaires used in international studies on Health Behavior
in School-aged Children (HBSC) (Mazur et al. 2009; Currie et al. 2004, 2008).
Cantril’s Ladder is a visual self-anchoring scale, graphically presented as a ladder with
numbered rungs. The subjects are required to mark on which rung they currently are in
their lives, knowing that the first rung (bottom of the ladder) is the worst and the ninth
rung (top of the ladder) is the best kind of life they might have. In cases when an 11-
rung ladder is used (scale 0–10), rungs from the sixth upwards signify considerable
satisfaction with life, whereas people who are dissatisfied usually score below that level
(Mazur et al. 2009). If a 9-point scale is used, level 5 is considered to be the cut off
point. After assessing the current life situation, the study participants were asked to
describe their life situation 5 years ago and in 5 years time.
Assessment of the Level of Dispositional Optimism
Life Orientation Test-Revised (LOT-R) is comprised of 10 statements 4 of which are
filler items (Poprawa and Juszczyński 2001). The subjects are instructed to determine to
what extent they agree with the given statements and to mark their answers on a 5-point
scale. The test score ranges from 0 to 24 points. The higher the score, the higher the
level of dispositional optimism of the respondent.
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Evaluation of Morphea Severity
The index of the extent, severity and activity of the skin changes in morphea
(Localized Scleroderma Severity Index—LoSSI) was developed by Arkachaisri and
Pino (2008). It is an observational scale, allowing for the assessment of the extent
of the changes, erythema, hardening of the skin and the activity of the plaques in
14 anatomic sites. The abovementioned parameters are assessed with the use of a
4-point scale (0-3) and then summed up. The obtained results range from 0 to 168
points. The higher the index, the more severe the disease (Arkachaisri and Pino
2008).
Statistical Analysis
All statistical analyses were performed using statistical program SPSS (SPSS Inc.,
Chicago, Ill, USA). Kolmogorow-Smirnov z-test was used for the assessment of the
normal distribution of the analyzed variables, whereas t-Student, U-Mann–Whitney
and Kruskal-Wallis tests were used for the evaluation of the significance of the
statistical difference between the groups. R-Spearman rank correlation coefficient
was used to determine the correlation between the variables.
Results
Mean duration of disease in the study group was 6 years (+/−9), although 68 % of the
patients were affected by the disease for no longer than 5 years. Mean values of the
Fig. 1 Comparison of the quality of life of morphea patients and healthy controls
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current, past and anticipated quality of life were 6.28 (SD=1.28), 6.77 (SD=1.43) and
6.79 (SD=1.84), respectively. In the control group, mean values of the current, past and
anticipated quality of life were 6.62 (SD=1.60), 6.45 (SD=1.60) and 7.49 (SD=1.64),
respectively. Mean values of dispositional optimism in the study and the control groups
were 16.02 (SD=4.13) and 18.06 (SD=4.45), respectively. As presented in Fig. 1, the
assessment of the anticipated life situation and the level of dispositional optimism are
statistically significantly lower in the group of morphea patients (p=0.032 and
p=0.023, respectively). No statistically significant differences between the subjective
evaluation of the current and the past level of life quality (p=0.168 and p=0.318) were
detected.
Statistical analysis revealed that gender does not differentiate the assessment
of the past and current quality of life level (p=0.667 and p=0.077, respectively), as
well as the level of dispositional optimism (p=0.225) in the study group. However,
statistically significant differences were found with regard to the anticipated life
situation (p=0.014). Female morphea patients evaluated their future quality of life
lower than the male morphea patients. No gender-related differences were found in
controls.
Further statistical analysis of the results (Kruskal-Wallis test) showed that
type of morphea did not differentiate the current, past and future evaluation of
life quality: p=0.175, p=0.620 and p=0.356, respectively (Fig. 2). It should be
noted, that due to its size (1 person) subgroup of patients with DM was
excluded from statistical analysis.
Mean value of LoSSI for 47 patients was 9.38 (SD=9.60). The objective
assessment of morphea did not correlate with any of the investigated psycho-
logical factors.
However, statistically significant relation between the level of dispositional opti-
mism and the current (p=0.002, r=0.43) and the anticipated (p<0.001, r=0.57) levels
of life quality was observed in morphea patients. Similar correlations were found in the
control group (p=0.02, r=0.38 and p=0.02, r=0.34, respectively).
Fig. 2 Comparison of the quality of life of morphea patients depending on the type of the disease
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Discussion
The obtained results allow us to conclude that evaluations of the current and past levels
of life quality in morphea patients and healthy controls are similar, whereas the struggle
with the disease significantly influences the assessment of the anticipated future. The
study revealed that morphea patients evaluate their life situation in 5 years time lower
than healthy controls.
On one hand, the absence of differences between the disease-affected people and
healthy controls regarding the assessment of the past and current level of life quality
may seem surprising. However, bad health does not have to be synonymous with poor
quality of life. Some patients are able to effectively adapt to the situation of the disease
and achieve their goals. It is noteworthy that Cantril’s Ladder is a much broader
construct than Health-Related Quality of Life (HRQoL). The latter is defined as
subjectively assessed influence of the disease and the therapy on the perception of
the quality of life (Bączyk et al. 2011; Świnoga et al. 2012), whereas, according to the
WHO recommendations, the general term of ‘life quality’ ought to include physical and
mental state, social relations, environment, religion, beliefs and opinions (Michalak
et al. 2009). Such understanding implies superiority of the quality of life in relation to
the concept of health. Perhaps that is why our results did not reveal any differences in
the assessment of the level of life quality depending on the type of the morphea. We
anticipated the patients with more serious course of the disease to have lower life
satisfaction than patients with a less severe type of morphea. The absence of differences
may have its source in a relatively small number of patients in the subgroups with
various subtypes of morphea.
It is noteworthy that, despite a relatively high evaluation of the current life quality,
similar to the healthy controls, morphea patients are more careful when anticipating
their future (in 5 years time) life situation. Most probably such uncertainty of the future
is typical of many patients with chronic diseases. It also seems safe to assume that
lower level of the anticipated quality of life is the result of the general attitude to life.
This study has shown that morphea patients have a lower level of optimism than
healthy people. However, in the light of the obtained results, it is not possible to
conclusively determine whether a lower level of optimism in disease-affected people is
the consequence of the difficulty to foresee the course of the disease or rather the cause
of careful predictions about the life situation in 5 years time, or both.
This study also indicates that there is no correlation between the clinical assessment of
morphea severity and the quality of life. Literature offers reports about extensive research
on the quality of life of people with dermatological diseases that did not confirm such
findings (Wahl et al. 1998; Szramka-Pawlak et al. 2013b) but also about numerous studies
that did confirm the presence of the correlation (Vardy et al. 2002; Reich and Griffiths
2008). Thus, the issue remains unresolved, as in our previous studies we proved that
severity of morphea lowers the quality of life in the aspect of psycho-social functioning
(Szramka-Pawlak et al. 2013a). The difference between our previous and current inves-
tigation was that our former study used a tool measuring the HRQoL. Therefore, in the
light of the abovementioned studies (Wahl et al. 1998; Vardy et al. 2002; Reich and
Griffiths 2008; Szramka-Pawlak et al. 2013a, b), it seems safe to conclude that the
assessment of the clinical severity of the disease is connected with HRQoL and not with
the general evaluation of life quality. That supports not only the previously mentioned
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differences between both constructs, but also subjectivity and multifactorial nature of the
general evaluation of life quality as a important psychological variable.
Our study also found that gender did not differentiate the assessment of the past and
the current quality of life. Only female patients suffering from morphea anticipated a
lower, when compared to males, level of life quality in the future, what supports our
earlier findings about lower level of life quality in case of females, especially regarding
emotional functioning (Szramka-Pawlak et al. 2013a). Literature data on this issue are
inconclusive and divergent. Some results indicate there are no differences between
genders regarding subjective well-being (Zalewska et al. 2003; Gupta and Gupta 1995;
Fortune et al. 1997), whereas other investigations report contrary results (Klein et al.
2011; Steuden and Janowski 2001). It is important to emphasize that the cited works
(Zalewska et al. 2003; Gupta and Gupta 1995; Fortune et al. 1997; Klein et al. 2011;
Steuden and Janowski 2001) explored the quality of life in people suffering from
dermatological diseases other than morphea. Thus, more extensive research is neces-
sary in order to evaluate the phenomenon and its causes.
The results of our study also indicate that there is a statistically significant correla-
tion between dispositional optimism and the current and anticipated assessment of life
quality. The finding is true of morphea patients as well as healthy controls. It is in
agreement with the claims of other investigation teams that optimism is generally an
important correlate of life quality and satisfaction (Schier and Carver 1992; Carver et al.
2010; Seligman 1998; Liney and Joseph 2004; Mannix et al. 2009).
Since optimism manifests itself in the general expectation of good outcome, its
connection with the quality of life, satisfaction and anticipated future seems clear. It is
therefore important to learn optimism and optimistic attitude to life (Carver et al. 2010;
Seligman 1998; Liney and Joseph 2004), as these healing factors may be particularly
valuable assets in the fight with dermatological diseases.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which
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are credited.
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